

TABLE 5.—SUMMARY

	O.C.'s	Pregnancy	Estrogens	Progestogens
Platelets.....	Increased number and possibly enhanced function.	Little effect.....	Enhanced function.....	No effect.
Coagulation.....	Definitely accelerated.....	Slightly accelerated.....	Accelerated by synthetic forms.	Do.
Level of activity of factors.	Increased.....	Increased.....		Do.
Fibrinolysis.....	do.....	Decreased.....	(?).....	Increased.

References

1. Abrams, A. A. Sequential estrogen and progestogen therapy. *Amer J Obstet Gynec* 96:1005, 1966.
2. Amris, C. J. and Starup, J. The coagulation mechanism in oral contraception. *Acta Obstet Gynec Scand* 46:78, 1967.
3. Amundson, B. A. and Pilgeram, L. O. Observations on a relationship between steroid metabolism and the concentration of plasma fibrinogen. *Thromb Diath Haemorrh* 10:400, 1963.
4. Banks, A. L., Rutherford, R. N., Coburn, W. A., and Welsh, R. L. The relationship of clotting factors to dosage levels of estrogen and progestogen-like combinations. *Int J Fertil* 11:277, 1966.
5. Beller, F. K., Douglas, G. W., Morris, R. H., and Johnson, H. J. The fibrinolytic enzyme system in pregnancy. *Amer J Obstet Gynec* 101:587, 1968.
6. Beller, F. K. and Porges, R. F. Blood coagulation and fibrinolytic enzyme studies during cyclic and continuous application of progestational agents. *Amer J Obstet Gynec* 97:448, 1967.
7. Bennett, N. B., Bennett, P. N., Fullerton, H. W., Ogston, C. M., and Ogston, D. Effect of oestriol on platelet adhesiveness and fibrinolysis in men. *Lancet* 2:881, 1966.
8. Bolton, C. H., Hampton, J. R., and Mitchell, J. R. Effect of oral contraceptive agents on platelets and plasma phospholipids. *Lancet* 1:1336, 1968.
9. Borchgrevink, C. F., Andersen, R., Hall, J., Hatteland, K., and Ursin-Holm, A. "Premarin" as a haemostatic agent: failure to demonstrate any laboratory or clinical effect. *Brit Med J* 2:1645, 1960.
10. Brakman, P. The fibrinolytic system in human blood during pregnancy. *Amer J Obstet Gynec* 94:14, 1966.
11. Brakman, P., Albrechtsen, O. K., and Astrup, T. Blood coagulation, fibrinolysis and contraceptive hormones. *JAMA* 199:69, 1967.
12. Brakman, P. and Astrup, T. Effects of female hormones, used as oral contraceptives, on the fibrinolytic system in blood. *Lancet* 2:10, 1964.
13. Brehm, H. Circulation, blood coagulation and clinical observations during hormonal suppression of ovulation. *Int J Fertil* 9:45, 1964.
14. Brodsky, I., Lewis, G., and Ross, E. Effect of pregnancy or a progestational drug on blood coagulation as measured by the Thrombotest. *Obstet Gynec* 24:213, 1964.
15. Bronstein, S. B., Stough, A., and Long, I. R. Double blind placebo controlled efficacy and safety study with Quinestrol. *Int J Fertil* 12:274, 1967.
16. Caspary, E. A. and Peberdy, M. Oral contraception and blood platelet adhesiveness. *Lancet* 1:1142, 1965.
17. Clemetson, C. A. B., Blair, L., and Brown, A. B. Capillary strength and the menstrual cycle. *Ann NY Acad Sci* 93:279, 1962.
18. Cohen, A. Double blind intensive safety and tolerance studies during Quinestrol therapy in elderly women. *Int J Fertil* 12:266, 1967.
19. Coopland, A., Alkjaersig, N., and Fletcher, A. P. Reduction in plasma factor XIII (FSF) concentration during pregnancy. *J Lab Clin Med* 73:144, 1969.
20. Daniel, D. G., Bloom, A. L., Giddings, J. C., Campbell, H., and Turnbull, A. C. Increased factor IX levels in puerperium during administration of diethylstilboestrol. *Brit. Med J* 1:801, 1968.
21. Dieckman, W. J. and Wegner, C. R. Studies of the blood in normal pregnancy. *Arch Intern Med* 53:353, 1934.